Getting muscles moving again after botulinum toxin: novel therapeutic challenges - PubMed (original) (raw)

Review

Getting muscles moving again after botulinum toxin: novel therapeutic challenges

Patrick G Foran et al. Trends Mol Med. 2003 Jul.

No abstract available

PubMed Disclaimer

Similar articles

• The journey of tetanus and botulinum neurotoxins in neurons.
  Lalli G, Bohnert S, Deinhardt K, Verastegui C, Schiavo G. Lalli G, et al. Trends Microbiol. 2003 Sep;11(9):431-7. doi: 10.1016/s0966-842x(03)00210-5. Trends Microbiol. 2003. PMID: 13678859 Review.
• Annexin 7: a non-SNARE proteolytic substrate for botulinum toxin type C in secreting chromaffin cells.
  Caohuy H, Pollard HB. Caohuy H, et al. Ann N Y Acad Sci. 2002 Oct;971:287-90. doi: 10.1111/j.1749-6632.2002.tb04481.x. Ann N Y Acad Sci. 2002. PMID: 12438137 No abstract available.
• Botulinum neurotoxins are metalloproteases specific for SNARE proteins involved in neuroexocytosis.
  Rossetto O, Seveso M, Caccin P, Montecucco C. Rossetto O, et al. Curr Probl Dermatol. 2002;30:117-25. doi: 10.1159/000060684. Curr Probl Dermatol. 2002. PMID: 12471705 Review. No abstract available.
• Intimate details of the most poisonous poison.
  Singh BR. Singh BR. Nat Struct Biol. 2000 Aug;7(8):617-9. doi: 10.1038/77900. Nat Struct Biol. 2000. PMID: 10932240
• Molecular targets of botulinum toxin at the mammalian neuromuscular junction.
  Whelchel DD, Brehmer TM, Brooks PM, Darragh N, Coffield JA. Whelchel DD, et al. Mov Disord. 2004 Mar;19 Suppl 8:S7-S16. doi: 10.1002/mds.20004. Mov Disord. 2004. PMID: 15027049

Cited by

• Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine.
  Robertson CE, Garza I. Robertson CE, et al. Neuropsychiatr Dis Treat. 2012;8:35-48. doi: 10.2147/NDT.S17923. Epub 2012 Jan 13. Neuropsychiatr Dis Treat. 2012. PMID: 22275844 Free PMC article.
• The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease.
  Opsenica I, Filipovic V, Nuss JE, Gomba LM, Opsenica D, Burnett JC, Gussio R, Solaja BA, Bavari S. Opsenica I, et al. Eur J Med Chem. 2012 Jul;53:374-9. doi: 10.1016/j.ejmech.2012.03.043. Epub 2012 Mar 30. Eur J Med Chem. 2012. PMID: 22516424 Free PMC article.
• Pharmacophore Refinement Guides the Rational Design of Nanomolar-Range Inhibitors of the Botulinum Neurotoxin Serotype A Metalloprotease.
  Nuss JE, Dong Y, Wanner LM, Ruthel G, Wipf P, Gussio R, Vennerstrom JL, Bavari S, Burnett JC. Nuss JE, et al. ACS Med Chem Lett. 2010 Oct 14;1(7):301-305. doi: 10.1021/ml100056v. ACS Med Chem Lett. 2010. PMID: 21116458 Free PMC article.
• Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A.
  Ho M, Goh CH, Brothers MC, Wang S, Young RL, Ou Y, Lui JN, Kalafatis M, Lan X, Wolf AE, Rienstra CM, Wilson BA. Ho M, et al. Protein Sci. 2012 Mar;21(3):318-26. doi: 10.1002/pro.2017. Protein Sci. 2012. PMID: 22170566 Free PMC article.
• Flux of signalling endosomes undergoing axonal retrograde transport is encoded by presynaptic activity and TrkB.
  Wang T, Martin S, Nguyen TH, Harper CB, Gormal RS, Martínez-Mármol R, Karunanithi S, Coulson EJ, Glass NR, Cooper-White JJ, van Swinderen B, Meunier FA. Wang T, et al. Nat Commun. 2016 Sep 30;7:12976. doi: 10.1038/ncomms12976. Nat Commun. 2016. PMID: 27687129 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database